Cangrelor Demonstrates Reduction in Early Ischemic Events in PCI Patients Compared with Clopidogrel
Cangrelor, an intravenous potent, rapid-acting P2Y12 inhibitor, reduces the risk of early ischemic events compared with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention, investigators reported during ACC.11, the American College of Cardiology’s 60th Annual Scientific Sessions.